159 related articles for article (PubMed ID: 8766424)
1. [5 years neuroblastoma screening in Austria: rate of participation, results and a comparison with other screening areas].
Kerbl R; Urban CE; Ladenstein R; Schnellauf C; Sitzwohl C; Lackner H; Gleispach H; Fauler G; Ambros PF; Ambros IM; Rumpler S; Gadner H; Spuller E; Höfler G; Amann G; Kytir J; Mutz I
Wien Klin Wochenschr; 1996; 108(13):398-403. PubMed ID: 8766424
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma screening in infants postponed after the sixth month of age: a trial to reduce "overdiagnosis" and to detect cases with "unfavorable" biologic features.
Kerbl R; Urban CE; Ladenstein R; Ambros IM; Spuller E; Mutz I; Amann G; Kovar H; Gadner H; Ambros PF
Med Pediatr Oncol; 1997 Jul; 29(1):1-10. PubMed ID: 9142198
[TBL] [Abstract][Full Text] [Related]
3. Screening for neuroblastoma: a review of the evidence.
Chamberlain J
J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
[TBL] [Abstract][Full Text] [Related]
4. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
Okazaki T; Kohno S; Mimaya J; Hasegawa S; Urushihara N; Yoshida A; Kawano S; Kusafuka J; Horikoshi Y; Takashima Y; Aoki K; Hamazaki M
Pediatr Surg Int; 2004 Jan; 20(1):27-32. PubMed ID: 14689211
[TBL] [Abstract][Full Text] [Related]
6. [Screening for neuroblastoma in infants aged 6 months. A method of testing].
Schrøder H; Møller J; Thomsen A; Skadborg R; Clausen N
Ugeskr Laeger; 1991 Dec; 153(51):3615-8. PubMed ID: 1776206
[TBL] [Abstract][Full Text] [Related]
7. Screening for neuroblastoma in the northern region of England. Laboratory aspects.
Seviour JA; McGill AC; Craft AW; Parker L; Bell S; Cole M; Smith J; Hawkins E; Brown J; Dale GA
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):332-6. PubMed ID: 1456399
[TBL] [Abstract][Full Text] [Related]
8. A 5-year (1990-1994) neuroblastoma screening feasibility study in France. Methodology and preliminary observations.
Mathieu P; Frappaz D; Chauvin F; Combaret V; Vercherat M; Brunat-Mentigny M; David L; Esteve J; Favrot M; Fouillat V; Greffe J; Lasset C; Renaud P; Philip T
Early Hum Dev; 1996 Sep; 46(1-2):177-96. PubMed ID: 9019414
[TBL] [Abstract][Full Text] [Related]
9. [Early neuroblastoma detection in Germany. On the status of the Hamburg-Stuttgart cooperative pilot study].
Schilling FH; Erttmann R; Dohrmann S; Erb N; Winkler K; Gross U; Treuner J
Klin Padiatr; 1992; 204(4):282-7. PubMed ID: 1518266
[TBL] [Abstract][Full Text] [Related]
10. Neuroblastoma screening in the United States: results of the Texas Outreach Program for neuroblastoma screening.
Ater JL; Gardner KL; Foxhall LE; Therrell BL; Bleyer WA
Cancer; 1998 Apr; 82(8):1593-602. PubMed ID: 9554539
[TBL] [Abstract][Full Text] [Related]
11. Screening for neuroblastoma in North America. Preliminary results of a pathology review from the Quebec Project.
Takeuchi LA; Hachitanda Y; Woods WG; Tuchman M; Lemieux B; Brisson L; Bernstein M; Brossard J; Leclerc JM; Byrne TD
Cancer; 1995 Dec; 76(11):2363-71. PubMed ID: 8635044
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma screening: labeling of HVA and VMA for stable isotope dilution gas chromatography-mass spectrometry.
Gleispach H; Huber E; Fauler G; Kerbl R; Urban C; Leis HJ
Nutrition; 1995; 11(5 Suppl):604-6. PubMed ID: 8748233
[TBL] [Abstract][Full Text] [Related]
13. Screening for neuroblastoma in North America. 2-year results from the Quebec Project.
Woods WG; Tuchman M; Bernstein ML; Leclerc JM; Brisson L; Look T; Brodeur GM; Shimada H; Hann HL; Robison LL
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):312-9. PubMed ID: 1456396
[TBL] [Abstract][Full Text] [Related]
14. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan.
Yamamoto K; Hayashi Y; Hanada R; Kikuchi A; Ichikawa M; Tanimura M; Yoshioka S
J Clin Oncol; 1995 Aug; 13(8):2033-8. PubMed ID: 7636545
[TBL] [Abstract][Full Text] [Related]
15. Urinary vanillylmandelic acid and homovanillic acid levels in randomly-sampled urine for the mass screening of neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
Jpn J Clin Oncol; 1990 Sep; 20(3):268-70. PubMed ID: 2255102
[TBL] [Abstract][Full Text] [Related]
16. Compliance in a screening program for neuroblastoma.
Campion P; Woods WG; Lemieux B
Prev Med; 1998; 27(4):590-6. PubMed ID: 9672953
[TBL] [Abstract][Full Text] [Related]
17. Vanillylmandelic acid, homovanillic acid, and catecholamines in urine of infants with neuroblastoma 6- to 11-month-old.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1986 Dec; 16(4):351-5. PubMed ID: 3795531
[TBL] [Abstract][Full Text] [Related]
18. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec.
Scriver CR; Gregory D; Bernstein M; Clow CL; Weisdorf T; Dougherty GE; Auray-Blais C; Giguère R; Lemieux B; Laberge C
CMAJ; 1987 May; 136(9):952-6. PubMed ID: 3105859
[TBL] [Abstract][Full Text] [Related]
20. Which cases are found and missed by neuroblastoma screening at 1 year? Results from the 1992 to 1995 study in three Federal States of Germany.
Berthold F; Baillot A; Hero B; Schurr P; Nerenz A; Hunneman DH; Sander J
J Clin Oncol; 1999 Apr; 17(4):1200. PubMed ID: 10561179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
